AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

4SC AG

Report Publication Announcement Apr 30, 2015

5_rns_2015-04-30_c524506e-282f-4ad8-bb95-0e0c88557d9c.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

News Details

Corporate | 30 April 2015 15:00

Announcement: 4SC AG to host conference call on 7 May 2015 to present first quarter results of 2015

4SC AG / Key word(s): Miscellaneous

2015-04-30 / 15:00


Announcement

4SC AG to host conference call on 7 May 2015 to present first quarter results of 2015

Planegg-Martinsried, Germany, 30 April 2015 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, will announce first quarter results 2015 of the 4SC Group and publish the Company’s report on the first three months of 2015 on 7 May 2015. On this day the Management Board of 4SC AG will host a conference call at 3pm CEST (9am EDT) to inform about the consolidated financial statements and important developments in the reporting period and beyond.

Investors, financial analysts, and journalists participating in the conference call can access via the following telephone numbers:

Date: 7 May 2015

Time: 3pm CEST (9am EDT)

Dial-in numbers:

+49-89-2030-31218 (Germany)

+44-20-3478-5300 (UK)

+1-646-254-3364 (USA)

+49-89-2030-31218 (other countries)

Conference-ID: 2868829

After the conference call a replay will be available in the section “Investors” / “Events & Presentations” / “Conference Calls & Webcasts” of the website www.4sc.com .

Ends

About 4SC

The Group managed by 4SC AG (ISIN DE000A14KL72) discovers and develops targeted, small-molecule drugs for treating diseases with high unmet medical needs in various cancer and autoimmune indications. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The Company’s pipeline comprises promising products that are in various stages of clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had a headcount of 66 employees (57 FTEs) at 31 December 2014. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Cautionary statement regarding forward-looking statements

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

For more information please visit www.4sc.com or contact:

4SC AG

Jochen Orlowski, Corporate Communications & Investor Relations

jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366

MC Services

Katja Arnold, Michelle Kremer

katja.arnold(at)mc-services.eu, Tel.: +49-89-2102-2840

The Trout Group

Chad Rubin

crubin(at)troutgroup.com, Tel.: +1-646-378-2947


2015-04-30 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: [email protected]
Internet: www.4sc.de
ISIN: DE000A14KL72
WKN: A14KL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News-Service
- - -
351675  2015-04-30

Talk to a Data Expert

Have a question? We'll get back to you promptly.